Virtual Date With Brooke Lima Part 2 46

Being in the grips of a nightmare is a common occurrence that we can all re=
late to, but we may never experience one exactly as a particular artist dep=
icts it. Here Fuseli conjures up a terrifying image filled with mystery and=
 panic, yet with a vague and disturbing familiarity. It suggests the way th=
e woman feels in the grip of a demonic nightmare, not what she sees. The Ni=
ghtmare was reproduced as an engraving; a copy hung in Sigmund Freud's apar=
tment in Vienna in the 1920s.

CVSHealth is committed to advancing health equity for the clients and commu=
nities we serve. Cross-sector communication and collaboration is key to adv=
ancing health equity, as it leverages and aligns strengths, skills, and res=
ources to advance common health goals. The necessity and success of these i=
nnovative and collaborative efforts has been highlighted during the respons=
e to the COVID-19 pandemic, with new partnerships emerging around data infr=
astructure, health communications, testing, vaccination efforts, and distri=
bution of critical supplies and equipment. Strong public-private partnershi=
ps aimed at addressing the social determinants of health (including quality=
 food, housing, transportation, education, jobs) can accelerate health equi=
ty. To advance the body of evidence and share best and promising practices =
on public-private partnerships, CVSHealth is working with the Journal of He=
alth Care for the Poor and Underserved to produce a supplemental issue dedi=
cated to highlighting the impact and lessons learned from public-private pa=
rtnerships focused on advancing health equity. In support of this objective=
 researchers from academia, industry, government, and community-based organ=
izations are invited to submit abstracts of 350 words or less concerning or=
iginal research on the public-private partnership health equity theme. The =
organizing committee will review the abstracts and issue invitations to sub=
mit full papers to those chosen. The details for submission are outlined be=
low.

Virtual Date With Brooke Lima Part 2 46
Download https://inutegyu.blogspot.com/?ah=3D2wI4nU



Thank you for visiting nature.com. You are using a browser version with lim=
ited support for CSS. To obtain the best experience, we recommend you use a=
 more up to date browser (or turn off compatibility mode in Internet Explor=
er). In the meantime, to ensure continued support, we are displaying the si=
te without styles and JavaScript.

For some of these analyses, the controls were simply existing population co=
ntrols without knowledge of SARS-CoV-2 infection or COVID-19 status, which =
may bias effect size estimates as some of these individuals may have either=
 become infected with SARS-CoV-2 or developed COVID-19. We perform several =
sensitivity analyses (Extended Data Fig. 7b, Supplementary Note and Supplem=
entary Table 4) in which we show that using population controls can be a va=
lid and powerful strategy for host genetic discovery of infectious disease,=
 and particularly those that are widespread and with rare severe outcomes.

Lastly, there are two loci in the 3p21.31 region with varying genes priorit=
ized by different methods for different independent signals. For the severi=
ty lead variant rs10490770:T>C, we prioritized CXCR6 with the Variant2Gene =
(V2G) algorithm26, although LZTFL1 is the closest gene. The CXCR6 has a rol=
e in chemokine signalling27 and LZTFL1 has been implicated in lung cancer28=
. rs2271616:G>T, which is associated with susceptibility, tags a complex re=
gion including several independent signals (Supplementary Note) that are al=
l located within the gene body of SLC6A20, which encodes a protein that is =
known to functionally interact with the SARS-CoV-2 receptor ACE229. However=
, none of the lead variants in the 3p21.31 region has been previously assoc=
iated with other traits or diseases in our PheWAS analysis. Although these =
results provide supporting in silico evidence for candidate causal gene pri=
oritization, further functional characterization is needed. Detailed locus =
descriptions and LocusZoom plots are provided in Supplementary Fig. 2.

The COVID-19 HGI has brought together investigators from across the world t=
o advance genetic discovery for SARS-CoV-2 infection and severe COVID-19 di=
sease. We report 13 genome-wide significant loci associated with some aspec=
t of SARS-CoV-2 infection or COVID-19. Many of these loci overlap with prev=
iously reported associations with lung-related phenotypes or autoimmune or =
inflammatory diseases, but some loci have no obvious candidate gene.

Four out of the thirteen genome-wide significant loci showed similar effect=
s in the reported SARS-CoV-2 infection analysis (a proxy for disease suscep=
tibility) and all-hospitalized COVID-19 (a proxy for disease severity). Of =
these, one locus was in close proximity to, yet independent of, the major g=
enetic signal for COVID-19 severity at the 3p21.31 locus. Notably, this loc=
us was associated with COVID-19 susceptibility rather than severity. The lo=
cus overlaps SLC6A20, which encodes an amino acid transporter that interact=
s with ACE2. Nonetheless, we caution that more data are needed to resolve t=
he nature of the relationship between genetic variation and COVID-19 at thi=
s locus, particularly as the physical proximity, LD structure and patterns =
of association suggest that untagged genetic variation could drive the asso=
ciation signal in the region. Our findings support the notion that some gen=
etic variants, most notably at the ABO and PPP1R15A loci, in addition to SL=
C6A20, can indeed affect susceptibility to infection rather than progressio=
n to severe COVID-19 once infected.

Care should be taken when interpreting the results from a meta-analysis bec=
ause of challenges with case and control ascertainment and collider bias (s=
ee Supplementary Note for a more detailed discussion on study limitations).=
 Drawing a comprehensive and reproducible map of the host genetics factors =
associated with COVID-19 severity and SARS-CoV-2 requires a sustained inter=
national effort to include diverse ancestries and study designs. To acceler=
ate downstream research and therapeutic discovery, the COVID-19 HGI regular=
ly publishes meta-analysis results from periodic data freezes on the websit=
e and provides an interactive explorer through which researchers can browse=
 the results and the genomic loci in more detail. Future work will be requi=
red to better understand the biological and clinical value of these finding=
s. Continued efforts to collect more samples and detailed phenotypic data s=
hould be endorsed globally, allowing for more thorough investigation of var=
iable, heritable symptoms, particularly in light of the newly emerging stra=
ins of SARS-CoV-2, which may provoke different host responses that lead to =
disease.

To prioritize candidate causal genes reported in full in Supplementary Tabl=
e 2, we used various gene prioritization approaches using both locus-based =
and similarity-based methods. Because we only describe the in silico gene p=
rioritization results without characterizing the actual functional activity=
 in vitro or in vivo, we aimed to provide a systematic approach to nominate=
 potential causal genes in a locus using the following criteria.

To recruit new international partner studies, we developed a workflow in wh=
ich new studies are registered and verified by a curation team ( ). Users c=
an explore the registered studies using a customized interface to find and =
contact studies with similar goals or approaches ( ). This helps to promote=
 organic assembly around focused projects that are adjacent to the centrali=
zed effort ( ). Visitors can query study information, including study desig=
n and research questions. Registered studies are visualized on a world map =
and are searchable by institutional affiliation, city and country.



To encourage data sharing and other forms of participation, we created a ro=
lling acknowledgements page ( ) and directions on how to contribute data to=
 the central meta-analysis effort ( -sharing). Upon the completion of each =
data freeze, we post summary statistics, plots and sample size breakdowns f=
or each phenotype and contributing cohort ( ). The results can be explored =
using an interactive web browser ( ). Several computational research groups=
 carry out follow-up analyses, which are made available for download ( -sil=
ico). To enhance scientific communication to the public, preliminary result=
s are described in blog posts by the scientific communications team and sha=
red on Twitter. The first post was translated to 30 languages with the help=
 of 85 volunteer translators. We compile publications and preprints submitt=
ed by participating groups and summarize genome-wide significant findings f=
rom these publications ( ).

The Missing Person Information Clearinghouse was established July 1, 1985, =
within the Department of Public Safety providing a program for compiling, c=
oordinating and disseminating information in relation to missing persons an=
d unidentified body/persons. Housed within the Division of Criminal Investi=
gation, the Clearinghouse assists in helping to locate missing persons thro=
ugh public awareness and cooperation, and in educating law enforcement offi=
cers and the general public about missing person issues.
 eebf2c3492